Trump Expedites FDA Review of Psychedelic Drug Treatments

President Trump signed an executive order directing the FDA to accelerate review of psychedelic drugs including ibogaine for medical treatment. The order aims to speed access to psychedelic-based therapies, particularly for treating post-traumatic stress disorder in military veterans. The reform could expand availability of these treatments to Americans seeking alternative mental health interventions.